AdCLD-CoV19 / Cellid - LARVOL DELTA

Dose-dependent serological profiling of AdCLD-CoV19-1 vaccine in adults. (PubMed, mSphere) - "Using a systems serology approach, we demonstrated significant dose-dependent differences in the humoral immune responses induced by the AdCLD-CoV19-1 chimeric adenovirus-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine, particularly against the SARS-CoV-2 spike 2 domain. These findings highlight the importance of assessing not only neutralizing antibody titers but also the quality and functionality of antibody responses when evaluating vaccine efficacy."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Strategy to develop broadly effective multivalent COVID-19 vaccines against emerging variants based on Ad5/35 platform. (PubMed, Proc Natl Acad Sci U S A) - "We developed bivalent vaccine AdCLD-CoV19-1 BA.5/BA.2.75 and trivalent vaccines AdCLD-CoV19-1 XBB/BN.1/BQ.1.1 and AdCLD-CoV19-1 XBB.1.5/BN.1/BQ.1.1 using an Ad5/35 platform-based non-replicating recombinant adenoviral vector...We found that the BA.5/BA.2.75 bivalent and the XBB/BN.1/BQ.1.1 and XBB.1.5/BN.1/BQ.1.1 trivalent vaccines exhibited improved cross-neutralization ability compared to their respective monovalent vaccines. These data suggest that the developed multivalent vaccines enhance immunity against circulating Omicron subvariants and effectively elicit neutralizing antibodies across a broad spectrum of SARS-CoV-2 variants."

Journal • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Boosting with variant-matched adenovirus-based vaccines promotes neutralizing antibody responses against SARS-CoV-2 Omicron sublineages in mice. (PubMed, Int J Antimicrob Agents) - "We previously developed AdCLD-CoV19-1, a non-replicating recombinant adenoviral vector that encode receptor binding domain of spike protein of ancestral SARS-CoV-2 strain...Of note, boosting with a vaccine targeting the BA.1 or BA.2 Omicron subvariant was most effective in neutralization against the pseudo-virus of BA.2.75 strain, whereas BA.4.1/5-adapted booster shots were most effective in neutralization against BQ.1, BQ1.1, and BF.7. Therefore, it is imperative to develop a vaccination strategy that can cover the unique spike mutations of currently circulating Omicron subvariants to prevent the next wave of COVID-19."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - P2a | N=150 | Completed | Sponsor: Cellid Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Completed | Sponsor: Cellid Co., Ltd. | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1 (clinicaltrials.gov) - P2b | N=4 | Terminated | Sponsor: Cellid Co., Ltd. | N=200 ➔ 4 | Trial completion date: May 2024 ➔ Nov 2022 | Not yet recruiting ➔ Terminated | Trial primary completion date: May 2024 ➔ Nov 2022; Study early terminated based on the sponsor(manufacture)'s decision

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - P2a | N=150 | Active, not recruiting | Sponsor: Cellid Co., Ltd. | Trial completion date: Dec 2022 ➔ May 2023

Trial completion date • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Cellid Co., Ltd. | Trial completion date: Dec 2022 ➔ May 2023

Trial completion date • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - P1 | N=40 | Active, not recruiting | Sponsor: Cellid Co., Ltd. | Trial completion date: Sep 2022 ➔ Dec 2022 | Trial primary completion date: Sep 2022 ➔ Dec 2022

Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity of COVID-19 Vaccine, AdCLD-CoV19-1 (clinicaltrials.gov) - P2b | N=200 | Not yet recruiting | Sponsor: International Vaccine Institute

New P2b trial • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - P2a | N=150 | Active, not recruiting | Sponsor: Cellid Co., Ltd. | Trial completion date: Apr 2022 ➔ Dec 2022

Trial completion date • Infectious Disease • Novel Coronavirus Disease

The Chimeric Adenovirus (Ad5/35) Expressing Engineered Spike Protein Confers Immunity against SARS-CoV-2 in Mice and Non-Human Primates. (PubMed, Vaccines (Basel)) - "While AdCLD-CoV19 maintained neutralizing antibody activity against various SARS-CoV-2 variants, it was reduced to single vaccination for β and ο variants, and the reduced neutralizing antibody activity was restored with booster shots. Hence, AdCLD-CoV19 can prevent SARS-CoV-2 with a single vaccination, and the new vaccine administration strategy that responds to various variants can maintain the efficacy of the vaccine."

Journal • Preclinical • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - P1; N=40; Active, not recruiting; Sponsor: Cellid Co., Ltd.; Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - P1; N=40; Recruiting; Sponsor: Cellid Co., Ltd.

Clinical • New P1 trial • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - P2a; N=150; Active, not recruiting; Sponsor: Cellid Co., Ltd.; Recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - P2a; N=150; Recruiting; Sponsor: Cellid Co., Ltd.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers (clinicaltrials.gov) - P2a; N=150; Not yet recruiting; Sponsor: Cellid Co., Ltd.

Clinical • New P2a trial • Infectious Disease • Novel Coronavirus Disease